Trial Condition(s):

Hypertension, Pulmonary

Examination of Ventavis (Iloprost) inhalation behavior using the I-Neb AAD system in patients with pulmonary arterial hypertension when switching the Iloprost nebulizer solution for inhalation from 10 μg/mL (V10) to 20 μg/mL (V20) (VENTASWITCH)

Bayer Identifier:

18838

ClinicalTrials.gov Identifier:

NCT02826252

EudraCT Number:

Not Available

Study Completed

Trial Purpose

The aim of this study is to examine inhalation behavior in patients enrolled in the German Ventavis patient support program Ventaplus when these patients are switched from Ventavis (Iloprost) 10 μg/mL to Ventavis (Iloprost) 20 μg/mL formulation.

Inclusion Criteria
- Patients aged ≥18 years at time of signing informed consent. 
- Patients, diagnosed with group 1 PAH.
- Patients must be enrolled in the German Ventavis patient support program Ventaplus.
- Patients who either already switched from V10 to V20 therapy or who agreed to do so according to their physician’s decision.
- Patients must have been on V10 therapy for at least 2 weeks.
- Written informed consent must be obtained.
Exclusion Criteria
- participation in other clinical or interventional study.

Trial Summary

Enrollment Goal
64
Trial Dates
black-arrow
Phase
4
Could I receive a placebo?
No
Products
Ventavis (Iloprost, BAYQ6256)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many locations, Germany

Status
Completed
 

Trial Design